I read virtually all of the postings here, noting several categories they fall into.
Many, understandably and quite legitimately, are focused on short-term trading gains. Buy some shares low, hold for a time, then sell high. Take a profit, and turn back around and buy at a new low, and sell again at a new high. Day-trading, momentum trading, etc. For those here for those purposes, I wish the best. In the coming weeks, months, and years, AVXL should, as the investment advisories proclaim about good trades, “out perform.”
Others, however, see AVXL as purely a long-term investment, targeting greatly advanced share prices and rewarding dividends in the (maybe) distant future. I’m in this group (and one below). I don’t know a Fibonacci pattern from an Elliot Wave Pattern. The oft-posted technical analysis charts here are beyond anything I can comprehend or use. Glad those with technical analysis proficiencies post these. They can be useful for others with TA interests.
I base my AVXL investment purely upon Anavex fundamentals, the soundness of the company’s management and technologies. Whenever I can be useful, I post a message explaining the biology of Anavex molecules against neurodegenerative diseases. I would think the majority of readers and posters on this board are in this category, long-term AVXL investors aiming for substantial, future share-price appreciation and dividend returns. Typical “retail” equity investors, we.
But, lastly, there is a final category of reader here, with unique and personal interests, related to personal experiences with Alzheimer’s and other CNS diseases. I am in this category, too; as I have a mild but confounding case of Hereditary Spastic Paraplegia, a rare genetic condition that causes the adductor muscles of my legs to remain tight, spastic; complicating normal walking. A study was done (in France) where human genes of my condition were inserted into lab rats, and they, like myself, had difficulties walking normally. Then, these transgenic rats were given, orally, Anavex 2-73 (or a close proprietary analogue) and wonderfully, the rats began to walk normally. I’m a biologist and I have every molecular biological reason to believe that once Anavex 2-73 is available, I will take it and resume, at least to some degree, normal ambulation. Personally, that would be wonderful.
But on a more somber note, I watched my dear mother attempt to care for my father in his last five years, slowly declining and eventually dying of Alzheimer’s. The hope Anavex 2-73 holds for Alzheimer’s victims and their care-givers transcends (for me at least) any of the remunerative rewards of AVXL ownership. The prospect that, literally, millions can find both relief and prevention of Alzheimer’s, Parkinson’s, Rett Syndrome, amyotrophic lateral sclerosis, and a host of other neurodegenerative diseases (in addition to various cancers, heart diseases, and others yet to be treated) rises far above the monetary rewards I anticipate.
All of this enters the supremely social, even spiritual realm; where profound “good” is done for multitudes who would otherwise suffer so horribly. I’ve seen that suffering in the last years of my father’s life. I am encouraged by the solid science of Anavex, the company’s management, and the many retail AVXL shareholders here who share these hopes.
For those who suffer, Godspeed, Anavex Life Sciences Corp.
